B7-H3 radiopharmaceutical enters first-in-human tumor trial
The first patient in the Phase 1/2a study received the investigational B7-H3-targeted radiopharmaceutical therapy at BAMF Health.
BAMF Health has administered the first dose of lutetium-177 BetaBart in a Phase 1/2a clinical trial evaluating the investigational radiopharmaceutical therapy in advanced solid tumors. The patient is a 51-year-old woman with metastatic lung cancer, according to BAMF Health.
The treatment is part of a study of 177Lu-BetaBart, also known as RV-01. Radiopharm Theranostics said the trial is the first-in-human study of the agent.
Radiopharm said the agent was developed by Radiopharm Ventures, its joint venture with the University of Texas MD Anderson Cancer Center. BAMF Health is serving as the radiopharmaceutical therapy trial center.
Lu-177 BetaBart is a Lu-177-labeled anti-B7-H3 monoclonal antibody. The study is enrolling patients with relapsed or refractory, locally advanced inoperable, or metastatic solid tumors, according to the ClinicalTrials.gov listing.
The Phase 1/2a trial is designed to assess safety, tolerability, biodistribution, pharmacokinetics, radiation dosimetry, and preliminary antitumor activity. It will also determine a recommended dose for future studies, Radiopharm said.
BAMF Health said the first patient had metastatic lung cancer involving 3 tumors in the left lung and lymph node lesions that had not responded to prior treatment.
“Dosing of the first patient in the Phase 1/2a trial of 177Lu-BetaBart marks an important milestone for Radiopharm,” said Riccardo Canevari, CEO and managing director of Radiopharm Theranostics.
ClinicalTrials.gov lists the study as recruiting. The trial record identifies Radiopharm Theranostics as the sponsor.
Company:Bamf Health
Sources
- Radiopharm Theranostics Doses First Patient in Phase 1/2a Clinical Study of BetaBart (RV-01). Press release
- Lung Cancer Patient is First in the World to Participate in New Therapy Trial. Company statement
- 177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors. Government document
About the author
RadiologySignal.com writersEditorial Team
Radiology Signal Staff covers developments across medical imaging, radiology AI, imaging informatics, clinical research, and radiology business. The team monitors primary sources, peer-reviewed studies, company announcements, society updates, and healthcare industry news to deliver concise reporting for imaging professionals.
More from this section
Pediatric ED imaging gaps persist by race and insurance status
A cohort study of 857,034 pediatric ED visits found that stronger hospital pediatric capability was not associated with narrower imaging-use differences by race, ethnicity, or insurance status.
Study finds wide variation in chest X-ray AI performance
A head-to-head study of 7 commercial AI devices found sensitivity ranged from 20.8% to 77.8% for lung cancer detection on chest X-rays.
MRI radiomics model predicts colorectal cancer subtype
The multicenter study found an MRI-based machine-learning radiomics score predicted CMS4 colorectal cancer and stratified recurrent metastasis risk.
Contrast tied to higher AKI risk in neonatal ICU study
The retrospective study found higher acute kidney injury rates in neonates exposed to iodinated contrast media, although most cases were stage 1.
Quantum BioPharma reports early PET tracer signal in MS study
The ongoing MGH study is evaluating [18F]3F4AP PET imaging for demyelinated neurons with intact axons in patients with multiple sclerosis.
Cochrane updates prostate cancer screening review
The updated review found PSA screening likely reduces prostate cancer deaths, but evidence remains unclear for newer screening strategies combining PSA, kallikrein testing, and MRI.
Stage 4 breast cancer diagnoses rise over decade
A cohort study of 761,471 people found de novo stage 4 breast cancer incidence increased by 1.2% per year from 2010 to 2021.
SIR backs genicular artery embolization for knee osteoarthritis
The Society of Interventional Radiology issued a position statement supporting genicular artery embolization for symptomatic knee osteoarthritis.
Fluoride, lead co-exposure linked to lower youth BMD
Researchers analyzed NHANES data from 2,378 U.S. children and adolescents who underwent DEXA scans from 2013 to 2016.
Stanford receives $3.9M ARPA-H grant for MR lymphangiography
Stanford Medicine received up to $3.9M from ARPA-H to advance MR lymphangiography. Andreas Loening, MD, PhD, will lead work on faster scans, lymphatic-specific contrast agents, and contrast-free flow assessment.
Bayer PET tracer meets cardiac amyloidosis endpoints
Bayer reported positive topline phase 3 REVEAL results for I-124 evuzamitide, an investigational PET/CT radiotracer for suspected cardiac amyloidosis. The study met its sensitivity and specificity endpoints.
14-minute MRx scan maps 20+ brain biomarkers without contrast
University of Illinois researchers developed multiplexed MRI to map more than 20 brain biomarkers in a single scan using standard clinical MRI systems.